REFERENCES
1. Frasca D. Several areas of overlap between obesity and aging indicate obesity as a biomarker of accelerated aging of human B cell function and antibody responses. Immun Ageing 2022;19:48.
2. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 2022;133:155217.
4. Afshin A, Forouzanfar MH, Reitsma MB, et al; GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13-27.
5. Schnabel F, Kornak U, Wollnik B. Premature aging disorders: a clinical and genetic compendium. Clin Genet 2021;99:3-28.
6. United Nations, Department of Economic and Social Affairs Population Division. World Population Prospects 2022: Summary of Results. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/wpp2022_summary_of_results.pdf. [Last accessed on 15 May 2024].
7. Li X, Cao X, Zhang J, et al. Accelerated aging mediates the associations of unhealthy lifestyles with cardiovascular disease, cancer, and mortality. J Am Geriatr Soc 2024;72:181-93.
8. Rudnicka E, Napierała P, Podfigurna A, Męczekalski B, Smolarczyk R, Grymowicz M. The World Health Organization (WHO) approach to healthy ageing. Maturitas 2020;139:6-11.
9. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014;159:709-13.
10. Li Z, Zhang Z, Ren Y, et al. Aging and age-related diseases: from mechanisms to therapeutic strategies. Biogerontology 2021;22:165-87.
12. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194-217.
13. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell 2023;186:243-78.
14. Global BMI Mortality Collaboration; Di Angelantonio E, Bhupathiraju ShN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-86.
15. Lung T, Jan S, Tan EJ, Killedar A, Hayes A. Impact of overweight, obesity and severe obesity on life expectancy of Australian adults. Int J Obes 2019;43:782-9.
16. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 2003;289:187-93.
17. Ruze R, Liu T, Zou X, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol 2023;14:1161521.
18. Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 2016;29:77-89.
19. Dikaiou P, Björck L, Adiels M, et al. Obesity, overweight and risk for cardiovascular disease and mortality in young women. Eur J Prev Cardiol 2021;28:1351-9.
20. Lee TH, Yau SY. From obesity to hippocampal neurodegeneration: pathogenesis and non-pharmacological interventions. Int J Mol Sci 2020;22:201.
22. Tam BT, Morais JA, Santosa S. Obesity and ageing: two sides of the same coin. Obes Rev 2020;21:e12991.
23. Reyes-Farias M, Fos-Domenech J, Serra D, Herrero L, Sánchez-Infantes D. White adipose tissue dysfunction in obesity and aging. Biochem Pharmacol 2021;192:114723.
24. Shinde AB, Song A, Wang QA. Brown adipose tissue heterogeneity, energy metabolism, and beyond. Front Endocrinol 2021;12:651763.
25. Li QOY, Soro-Arnaiz I, Aragonés J. Age-dependent obesity and mitochondrial dysfunction. Adipocyte 2017;6:161-6.
26. Zhang YX, Ou MY, Yang ZH, Sun Y, Li QF, Zhou SB. Adipose tissue aging is regulated by an altered immune system. Front Immunol 2023;14:1125395.
27. Man K, Kallies A, Vasanthakumar A. Resident and migratory adipose immune cells control systemic metabolism and thermogenesis. Cell Mol Immunol 2022;19:421-31.
28. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021;320:C375-91.
29. Xu C, Mathews AE, Rodrigues C, et al. Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr ESPEN 2018;24:148-55.
30. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017;542:177-85.
31. Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy 2018;14:207-15.
32. Aman Y, Schmauck-Medina T, Hansen M, et al. Autophagy in healthy aging and disease. Nat Aging 2021;1:634-50.
33. Faghfouri AH, Khajebishak Y, Payahoo L, Faghfuri E, Alivand M. PPAR-gamma agonists: potential modulators of autophagy in obesity. Eur J Pharmacol 2021;912:174562.
34. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev 2017;35:200-21.
35. Wei S, Nguyen TT, Zhang Y, Ryu D, Gariani K. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol 2023;14:1185221.
36. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018;14:513-37.
38. Wagenaar CA, Dekker LH, Navis GJ. Prevalence of sarcopenic obesity and sarcopenic overweight in the general population: the lifelines cohort study. Clin Nutr 2021;40:4422-9.
39. Gao Q, Mei F, Shang Y, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr 2021;40:4633-41.
40. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 2022;15:321-35.
41. Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652-4.
42. Crooks B, Stamataki NS, McLaughlin JT. Appetite, the enteroendocrine system, gastrointestinal disease and obesity. Proc Nutr Soc 2021;80:50-8.
43. Westfall S, Lomis N, Kahouli I, Dia SY, Singh SP, Prakash S. Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. Cell Mol Life Sci 2017;74:3769-87.
44. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787-803.
45. O'toole PW, Claesson MJ. Gut microbiota: Changes throughout the lifespan from infancy to elderly. Int Dairy J 2010;20:281-91.
46. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007;104:979-84.
47. Rinninella E, Tohumcu E, Raoul P, et al. The role of diet in shaping human gut microbiota. Best Pract Res Clin Gastroenterol 2023;62-3:101828.
48. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. PeerJ 2019;7:e7502.
49. Liu BN, Liu XT, Liang ZH, Wang JH. Gut microbiota in obesity. World J Gastroenterol 2021;27:3837-50.
50. Ling Z, Liu X, Cheng Y, Yan X, Wu S. Gut microbiota and aging. Crit Rev Food Sci Nutr 2022;62:3509-34.
51. Stojanov S, Berlec A, Štrukelj B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms 2020;8:1715.
52. DeJong EN, Surette MG, Bowdish DME. The gut microbiota and unhealthy aging: disentangling cause from consequence. Cell Host Microbe 2020;28:180-9.
53. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4.
54. Aoun A, Darwish F, Hamod N. The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss. Prev Nutr Food Sci 2020;25:113-23.
55. Magne F, Gotteland M, Gauthier L, et al. The firmicutes/bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients 2020;12:1474.
56. Castaner O, Goday A, Park YM, et al. The gut microbiome profile in obesity: a systematic review. Int J Endocrinol 2018;2018:4095789.
57. Peters BA, Shapiro JA, Church TR, et al. A taxonomic signature of obesity in a large study of American adults. Sci Rep 2018;8:9749.
58. Koutoukidis DA, Jebb SA, Zimmerman M, et al. The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis. Gut Microbes 2022;14:2020068.
59. Vaz M, Pereira SS, Monteiro MP. Metabolomic signatures after bariatric surgery - a systematic review. Rev Endocr Metab Disord 2022;23:503-19.
60. Tavassol ZH, Ejtahed HS, Atlasi R, et al. Alteration in gut microbiota composition of older adults is associated with obesity and its indices: a systematic review. J Nutr Health Aging 2023;27:817-23.
61. Kesavelu D, Jog P. Current understanding of antibiotic-associated dysbiosis and approaches for its management. Ther Adv Infect Dis 2023;10:20499361231154443.
62. Malik JA, Zafar MA, Lamba T, Nanda S, Khan MA, Agrewala JN. The impact of aging-induced gut microbiome dysbiosis on dendritic cells and lung diseases. Gut Microbes 2023;15:2290643.
63. Hung CC, Chang CC, Huang CW, Nouchi R, Cheng CH. Gut microbiota in patients with Alzheimer’s disease spectrum: a systematic review and meta-analysis. Aging 2022;14:477-96.
64. Almeida HM, Sardeli AV, Conway J, Duggal NA, Cavaglieri CR. Comparison between frail and non-frail older adults’ gut microbiota: a systematic review and meta-analysis. Ageing Res Rev 2022;82:101773.
65. Palmas V, Pisanu S, Madau V, et al. Gut microbiota markers and dietary habits associated with extreme longevity in healthy sardinian centenarians. Nutrients 2022;14:2436.
66. Biagi E, Franceschi C, Rampelli S, et al. Gut microbiota and extreme longevity. Curr Biol 2016;26:1480-5.
67. Luan Z, Sun G, Huang Y, et al. Metagenomics study reveals changes in gut microbiota in centenarians: a cohort study of Hainan centenarians. Front Microbiol 2020;11:1474.
68. Sepp E, Smidt I, Rööp T, et al. Comparative analysis of gut microbiota in centenarians and young people: impact of eating habits and childhood living environment. Front Cell Infect Microbiol 2022;12:851404.
69. Pang S, Chen X, Lu Z, et al. Longevity of centenarians is reflected by the gut microbiome with youth-associated signatures. Nat Aging 2023;3:436-49.
70. Zhang S, Zeng B, Chen Y, et al. Gut microbiota in healthy and unhealthy long-living people. Gene 2021;779:145510.
71. Wilmanski T, Diener C, Rappaport N, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab 2021;3:274-86.
73. Mohammad S, Thiemermann C. Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front Immunol 2020;11:594150.
74. Ghosh S, Lertwattanarak R, Garduño Jde J, et al. Elevated muscle TLR4 expression and metabolic endotoxemia in human aging. J Gerontol A Biol Sci Med Sci 2015;70:232-46.
75. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018;14:576-90.
76. Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr 2020;74:1251-62.
77. Vatanen T, Kostic AD, d’Hennezel E, et al; DIABIMMUNE Study Group. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 2016;165:842-53.
78. Ahmad R, Rah B, Bastola D, Dhawan P, Singh AB. Obesity-induces organ and tissue specific tight junction restructuring and barrier deregulation by claudin switching. Sci Rep 2017;7:5125.
79. Nagpal R, Newman TM, Wang S, Jain S, Lovato JF, Yadav H. Obesity-linked gut microbiome dysbiosis associated with derangements in gut permeability and intestinal cellular homeostasis independent of diet. J Diabetes Res 2018;2018:3462092.
80. Yao D, Dai W, Dong M, Dai C, Wu S. MUC2 and related bacterial factors: therapeutic targets for ulcerative colitis. EBioMedicine 2021;74:103751.
81. Hussain M, Umair Ijaz M, Ahmad MI, et al. Meat proteins in a high-fat diet have a substantial impact on intestinal barriers through mucus layer and tight junction protein suppression in C57BL/6J mice. Food Funct 2019;10:6903-14.
82. Ghosh TS, Shanahan F, O'Toole PW. The gut microbiome as a modulator of healthy ageing. Nat Rev Gastroenterol Hepatol 2022;19:565-84.
83. Wu M, Wu Y, Li J, Bao Y, Guo Y, Yang W. The dynamic changes of gut microbiota in Muc2 deficient mice. Int J Mol Sci 2018;19:2809.
84. Chen Z, Luo J, Li J, et al. Foxo1 controls gut homeostasis and commensalism by regulating mucus secretion. J Exp Med 2021;218:e20210324.
85. Tran L, Greenwood-Van Meerveld B. Age-associated remodeling of the intestinal epithelial barrier. J Gerontol A Biol Sci Med Sci 2013;68:1045-56.
86. Oami T, Abtahi S, Shimazui T, et al. Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. Proc Natl Acad Sci U S A 2024;121:e2217877121.
87. Cuevas-Sierra A, Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Martinez JA. Diet, gut microbiota, and obesity: links with host genetics and epigenetics and potential applications. Adv Nutr 2019;10:S17-30.
88. Anachad O, Taouil A, Taha W, Bennis F, Chegdani F. The implication of short-chain fatty acids in obesity and diabetes. Microbiol Insights 2023;16:11786361231162720.
89. Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett 2014;588:4223-33.
90. Ecklu-Mensah G, Choo-Kang C, Maseng MG, et al. Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study. Nat Commun 2023;14:5160.
91. de la Cuesta-Zuluaga J, Mueller NT, Álvarez-Quintero R, et al. Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors. Nutrients 2018;11:51.
92. Rampelli S, Candela M, Turroni S, et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing. Aging 2013;5:902-12.
93. Jones ML, Martoni CJ, Ganopolsky JG, Labbé A, Prakash S. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opin Biol Ther 2014;14:467-82.
94. Frommherz L, Bub A, Hummel E, et al. Age-related changes of plasma bile acid concentrations in healthy adults--results from the cross-sectional KarMeN study. PLoS One 2016;11:e0153959.
95. Badal VD, Vaccariello ED, Murray ER, et al. The gut microbiome, aging, and longevity: a systematic review. Nutrients 2020;12:3759.
96. Hersoug LG, Møller P, Loft S. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity. Nutr Res Rev 2018;31:153-63.
97. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25.
98. Ghosh AK, O'Brien M, Mau T, Yung R. Toll-like receptor 4 (TLR4) deficient mice are protected from adipose tissue inflammation in aging. Aging 2017;9:1971-82.
99. Tilves CM, Zmuda JM, Kuipers AL, et al. Association of lipopolysaccharide-binding protein with aging-related adiposity change and prediabetes among African ancestry men. Diabetes Care 2016;39:385-91.
100. Liu X, Lu L, Yao P, et al. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese. Diabetologia 2014;57:1834-41.
101. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism 2017;68:133-44.
102. Kavanagh K, Hsu FC, Davis AT, Kritchevsky SB, Rejeski WJ, Kim S. Biomarkers of leaky gut are related to inflammation and reduced physical function in older adults with cardiometabolic disease and mobility limitations. Geroscience 2019;41:923-33.
104. Marizzoni M, Cattaneo A, Mirabelli P, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer’s disease. J Alzheimers Dis 2020;78:683-97.
105. Kesika P, Suganthy N, Sivamaruthi BS, Chaiyasut C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sci 2021;264:118627.
106. Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR. Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathol Commun 2023;11:42.
107. Serrano-Pozo A, Muzikansky A, Gómez-Isla T, et al. Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease. J Neuropathol Exp Neurol 2013;72:462-71.
108. Ahmad MH, Fatima M, Mondal AC. Role of hypothalamic-pituitary-adrenal axis, hypothalamic-pituitary-gonadal axis and insulin signaling in the pathophysiology of Alzheimer’s disease. Neuropsychobiology 2019;77:197-205.
109. Werdermann M, Berger I, Scriba LD, et al. Insulin and obesity transform hypothalamic-pituitary-adrenal axis stemness and function in a hyperactive state. Mol Metab 2021;43:101112.
110. Browning KN, Verheijden S, Boeckxstaens GE. The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology 2017;152:730-44.
111. Sen T, Cawthon CR, Ihde BT, et al. Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. Physiol Behav 2017;173:305-17.
112. Phillips RJ, Walter GC, Powley TL. Age-related changes in vagal afferents innervating the gastrointestinal tract. Auton Neurosci 2010;153:90-8.
113. Han Y, Wang B, Gao H, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. J Inflamm Res 2022;15:6213-30.
114. Marsh SE, Blurton-Jones M. Examining the mechanisms that link β-amyloid and α-synuclein pathologies. Alzheimers Res Ther 2012;4:11.
115. Garvey WT, Mechanick JI, Brett EM, et al; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22:1-203.
116. Hernández-Reyes A, Cámara-Martos F, Molina-Luque R, Romero-Saldaña M, Molina-Recio G, Moreno-Rojas R. Changes in body composition with a hypocaloric diet combined with sedentary, moderate and high-intense physical activity: a randomized controlled trial. BMC Womens Health 2019;19:167.
117. Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest 2021;131:140065.
118. Di Rosa C, Lattanzi G, Spiezia C, et al. Mediterranean diet versus very low-calorie ketogenic diet: effects of reaching 5% body weight loss on body composition in subjects with overweight and with obesity-a cohort study. Int J Environ Res Public Health 2022;19:13040.
119. Bruci A, Tuccinardi D, Tozzi R, et al. Very low-calorie ketogenic diet: a safe and effective tool for weight loss in patients with obesity and mild kidney failure. Nutrients 2020;12:333.
120. Dong TS, Luu K, Lagishetty V, et al. A high protein calorie restriction diet alters the gut microbiome in obesity. Nutrients 2020;12:3221.
121. Tettamanzi F, Bagnardi V, Louca P, et al. A high protein diet is more effective in improving insulin resistance and glycemic variability compared to a mediterranean diet-a cross-over controlled inpatient dietary study. Nutrients 2021;13:4380.
122. Kheniser K, Saxon DR, Kashyap SR. Long-term weight loss strategies for obesity. J Clin Endocrinol Metab 2021;106:1854-66.
123. Machado AM, Guimarães NS, Bocardi VB, et al. Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis. Clin Nutr ESPEN 2022;49:138-53.
124. Jackson VM, Breen DM, Fortin JP, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discov 2015;10:825-39.
125. van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol 2019;15:274-87.
126. Perry AS, Tanriverdi K, Risitano A, et al. The inflammatory proteome, obesity, and medical weight loss and regain in humans. Obesity 2023;31:150-8.
127. Fitzgerald KN, Hodges R, Hanes D, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging 2021;13:9419-32.
128. Waziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging 2023;3:248-57.
129. Lilja S, Stoll C, Krammer U, et al. Five days periodic fasting elevates levels of longevity related christensenella and sirtuin expression in humans. Int J Mol Sci 2021;22:2331.
130. McGrattan AM, McGuinness B, McKinley MC, et al. Diet and inflammation in cognitive ageing and Alzheimer’s disease. Curr Nutr Rep 2019;8:53-65.
131. Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr 2020;11:1150-60.
132. Elsayed MM, Rabiee A, El Refaye GE, Elsisi HF. Aerobic exercise with mediterranean-DASH intervention for neurodegenerative delay diet promotes brain cells’ longevity despite sex hormone deficiency in postmenopausal women: a randomized controlled trial. Oxid Med Cell Longev 2022;2022:4146742.
133. Liu X, Morris MC, Dhana K, et al. Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) study: rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline. Contemp Clin Trials 2021;102:106270.
134. Office for Health Improvement & Disparities. A consensus on healthy ageing. Available from: https://www.gov.uk/government/publications/healthy-ageing-consensus-statement/a-consensus-on-healthy-ageing. [Last accessed on 15 May 2024].
135. Legrand R, Nuemi G, Poulain M, Manckoundia P. Description of lifestyle, including social life, diet and physical activity, of people ≥ 90 years living in Ikaria, a longevity blue zone. Int J Environ Res Public Health 2021;18:6602.
136. Fastame MC. Well-being, food habits, and lifestyle for longevity. Preliminary evidence from the sardinian centenarians and long-lived people of the Blue Zone. Psychol Health Med 2022;27:728-33.
137. Zhang H, Shi N, Diao Z, Chen Y, Zhang Y. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: past and future. Genes Dis 2021;8:38-47.
138. Sciorati C, Gamberale R, Monno A, et al. Pharmacological blockade of TNFα prevents sarcopenia and prolongs survival in aging mice. Aging 2020;12:23497-508.
139. Amor C, Fernández-Maestre I, Chowdhury S, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat Aging 2024;4:336-49.
140. Avcı A, Avcı D, Ulaş Y, Ertaş R. Can biologic agents improve treatment success in obese patients with psoriasis vulgaris: a retrospective review of 320 patients with psoriasis vulgaris. Dermatol Pract Concept 2024;14:e2024058.
141. Anghel F, Nitusca D, Cristodor P. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis. Life 2021;11:1316.
142. Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-α inhibitors on body weight and BMI: a systematic review and meta-analysis. Front Pharmacol 2020;11:481.
143. Barros G, Duran P, Vera I, Bermúdez V. Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci 2022;23:7499.
144. Grunvald E, Shah R, Hernaez R, et al; AGA Clinical Guidelines Committee. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163:1198-225.
145. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine 2023;58:101882.
147. Suran M. As ozempic’s popularity soars, here’s what to know about semaglutide and weight loss. JAMA 2023;329:1627-9.
148. Han SH, Safeek R, Ockerman K, et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a google trends analysis. Aesthet Surg J 2023;44:60-7.
149. Zhang Y, Li Q, Niu Y, et al. Research progress on aging mechanism and drugs and the role of stem cells in anti-aging process. Exp Gerontol 2023;179:112248.
150. Mohammed I, Hollenberg MD, Ding H, Triggle CR. A critical review of the evidence that metformin is a putative anti-aging drug that enhances healthspan and extends lifespan. Front Endocrinol 2021;12:718942.
151. Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev 2017;40:31-44.
152. U.S. Food and Drug Administration. GLUCOPHAGE® (metformin hydrochloride) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf. [Last accessed on 15 May 2024].
153. LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev 2021;42:77-96.
154. Kulkarni AS, Brutsaert EF, Anghel V, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell 2018;17:e12723.
155. U.S. Food and Drug Administration. Rapamune (sirolimus) Label. Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf. [Last accessed on 15 May 2024].
156. Juricic P, Lu YX, Leech T, et al. Long-lasting geroprotection from brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy. Nat Aging 2022;2:824-36.
157. Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization. Aging Cell 2022;21:e13596.
158. Ershad M, Naji A, Vearrier D. N-acetylcysteine. Treasure island (FL): StatPearls Publishing; 2024.
159. Sohouli MH, Eslamian G, Malekpour Alamdari N, et al. Effects of N-acetylcysteine on aging cell and obesity complications in obese adults: a randomized, double-blind clinical trial. Front Nutr 2023;10:1237869.
160. U.S. Food and Drug Administration. SprycelTM (dasatinib) tablets. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021986s000_Sprycel__PRNTLBL.pdf. [Last accessed on 15 May 2024].
161. Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, Zhu Y. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest 2022;132:e158450.
162. Scarpellini E, Rinninella E, Basilico M, et al. From pre- and probiotics to post-biotics: a narrative review. Int J Environ Res Public Health 2021;19:37.
164. Green M, Arora K, Prakash S. Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci 2020;21:2890.
165. Davani-Davari D, Negahdaripour M, Karimzadeh I, et al. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 2019;8:92.
166. Canfora EE, van der Beek CM, Hermes GDA, et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 2017;153:87-97.e3.
167. Arnold JW, Roach J, Fabela S, et al. The pleiotropic effects of prebiotic galacto-oligosaccharides on the aging gut. Microbiome 2021;9:31.
168. Qiang X, Yonglie C, Qianbing W. Health benefit application of functional oligosaccharides. Carbohydr Polym 2009;77:435-41.
169. Ma C, Yang K, Wang Y, Dai X. Anti-aging effect of agar oligosaccharide on male drosophila melanogaster and its preliminary mechanism. Mar Drugs 2019;17:632.
170. D’Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 2015;106:256-71.
171. Jung CH, Cho I, Ahn J, Jeon TI, Ha TY. Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res 2013;27:139-43.
172. Cui Z, Zhao X, Amevor FK, et al. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Front Immunol 2022;13:943321.
173. Saccon TD, Nagpal R, Yadav H, et al. Senolytic combination of dasatinib and quercetin alleviates intestinal senescence and inflammation and modulates the gut microbiome in aged mice. J Gerontol A Biol Sci Med Sci 2021;76:1895-905.
174. Gonzales MM, Garbarino VR, Marques Zilli E, et al. Senolytic therapy to modulate the progression of Alzheimer’s disease (SToMP-AD): a pilot clinical trial. J Prev Alzheimers Dis 2022;9:22-9.
175. Zhao L, Zhu X, Xia M, et al. Quercetin ameliorates gut microbiota dysbiosis that drives hypothalamic damage and hepatic lipogenesis in monosodium glutamate-induced abdominal obesity. Front Nutr 2021;8:671353.
176. Shi T, Bian X, Yao Z, Wang Y, Gao W, Guo C. Quercetin improves gut dysbiosis in antibiotic-treated mice. Food Funct 2020;11:8003-13.
177. Yuan H, Li Y, Ling F, et al. The phytochemical epigallocatechin gallate prolongs the lifespan by improving lipid metabolism, reducing inflammation and oxidative stress in high-fat diet-fed obese rats. Aging Cell 2020;19:e13199.
178. Huang LH, Liu CY, Wang LY, Huang CJ, Hsu CH. Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial. BMC Complement Altern Med 2018;18:294.
179. D'Amico D, Olmer M, Fouassier AM, et al. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging Cell 2022;21:e13662.
180. Kong S, Huang X, Cao H, et al. Anti-obesity effects of galacto-oligosaccharides in obese rats. Eur J Pharmacol 2022;917:174728.
181. Krumbeck JA, Rasmussen HE, Hutkins RW, et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome 2018;6:121.
182. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.
183. Kechagia M, Basoulis D, Konstantopoulou S, et al. Health benefits of probiotics: a review. ISRN Nutr 2013;2013:481651.
184. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017;15:73.
185. Tsai YC, Cheng LH, Liu YW, Jeng OJ, Lee YK. Gerobiotics: probiotics targeting fundamental aging processes. Biosci Microbiota Food Health 2021;40:1-11.
186. Tomaro-Duchesneau C, Saha S, Malhotra M, et al. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl Microbiol Biotechnol 2014;98:115-26.
187. Westfall S, Lomis N, Prakash S. A polyphenol-rich prebiotic in combination with a novel probiotic formulation alleviates markers of obesity and diabetes in Drosophila. J Funct Foods 2018;48:374-86.
188. Iqbal UH, Westfall S, Prakash S. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artif Cells Nanomed Biotechnol 2018;46:S116-24.
189. Lee E, Jung SR, Lee SY, Lee NK, Paik HD, Lim SI. Lactobacillus plantarum strain Ln4 attenuates diet-induced obesity, insulin resistance, and changes in hepatic mRNA levels associated with glucose and lipid metabolism. Nutrients 2018;10:643.
190. van Beek AA, Sovran B, Hugenholtz F, et al. Supplementation with Lactobacillus plantarum WCFS1 prevents decline of mucus barrier in colon of accelerated aging Ercc1-/Δ7 mice. Front Immunol 2016;7:408.
191. Lee CC, Liao YC, Lee MC, et al. Lactobacillus plantarum TWK10 attenuates aging-associated muscle weakness, bone loss, and cognitive impairment by modulating the gut microbiome in mice. Front Nutr 2021;8:708096.
192. Kang Y, Kang X, Yang H, et al. Lactobacillus acidophilus ameliorates obesity in mice through modulation of gut microbiota dysbiosis and intestinal permeability. Pharmacol Res 2022;175:106020.
193. Vallianou N, Stratigou T, Christodoulatos GS, Tsigalou C, Dalamaga M. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr Obes Rep 2020;9:179-92.
194. Jang AY, Rod-In W, Monmai C, et al. Anti-inflammatory potential of Lactobacillus reuteri LM1071 via eicosanoid regulation in LPS-stimulated RAW264.7 cells. J Appl Microbiol 2022;133:67-75.
195. Dias AMM, Douhard R, Hermetet F, et al. Lactobacillus stress protein GroEL prevents colonic inflammation. J Gastroenterol 2021;56:442-55.
196. Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in human health and diseases. Front Microbiol 2018;9:757.
197. Jones ML, Martoni CJ, Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating
198. Tenorio-Jiménez C, Martínez-Ramírez MJ, Tercero-Lozano M, et al. Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR). BMC Complement Altern Med 2018;18:306.
199. Million M, Angelakis E, Maraninchi M, et al. Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int J Obes 2013;37:1460-6.
200. Álvarez-Arraño V, Martín-Peláez S. Effects of probiotics and synbiotics on weight loss in subjects with overweight or obesity: a systematic review. Nutrients 2021;13:3627.
201. Chen LH, Chang SS, Chang HY, et al. Probiotic supplementation attenuates age-related sarcopenia via the gut-muscle axis in SAMP8 mice. J Cachexia Sarcopenia Muscle 2022;13:515-31.
202. Cheng LH, Chou PY, Hou AT, Huang CL, Shiu WL, Wang S. Lactobacillus paracasei PS23 improves cognitive deficits via modulating the hippocampal gene expression and the gut microbiota in D-galactose-induced aging mice. Food Funct 2022;13:5240-51.
203. Chen LH, Huang SY, Huang KC, et al. Lactobacillus paracasei PS23 decelerated age-related muscle loss by ensuring mitochondrial function in SAMP8 mice. Aging 2019;11:756-70.
204. Corpuz HM, Ichikawa S, Arimura M, et al. Long-term diet supplementation with Lactobacillus paracasei K71 Prevents age-related cognitive decline in senescence-accelerated mouse prone 8. Nutrients 2018;10:762.
205. Moro-García MA, Alonso-Arias R, Baltadjieva M, et al. Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects. Age 2013;35:1311-26.
206. Abdelhamid AG, El-Masry SS, El-Dougdoug NK. Probiotic Lactobacillus and Bifidobacterium strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining. EPMA J 2019;10:337-50.
207. Lee SY, Lee BH, Park JH, Park MS, Ji GE, Sung MK. Bifidobacterium bifidum BGN4 paraprobiotic supplementation alleviates experimental colitis by maintaining gut barrier and suppressing nuclear factor kappa B activation signaling molecules. J Med Food 2022;25:146-57.
208. Marras L, Caputo M, Bisicchia S, et al. The role of bifidobacteria in predictive and preventive medicine: a focus on eczema and hypercholesterolemia. Microorganisms 2021;9:836.
209. Rahman MS, Lee Y, Park DS, Kim YS. Bifidobacterium bifidum DS0908 and Bifidobacterium longum DS0950 culture-supernatants ameliorate obesity-related characteristics in mice with high-fat diet-induced obesity. J Microbiol Biotechnol 2023;33:96-105.
210. Wang J, Qie J, Zhu D, et al. The landscape in the gut microbiome of long-lived families reveals new insights on longevity and aging - relevant neural and immune function. Gut Microbes 2022;14:2107288.
211. Mo SJ, Lee K, Hong HJ, et al. Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on overweight and the gut microbiota in humans: randomized, double-blinded, placebo-controlled clinical trial. Nutrients 2022;14:2484.
212. Sohn M, Na GY, Chu J, Joung H, Kim BK, Lim S. Efficacy and safety of Lactobacillus plantarum K50 on lipids in Koreans with obesity: a randomized, double-blind controlled clinical trial. Front Endocrinol 2021;12:790046.
213. Rahayu ES, Mariyatun M, Putri Manurung NE, et al. Effect of probiotic Lactobacillus plantarum Dad-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J Gastroenterol 2021;27:107-28.
214. Michael DR, Davies TS, Jack AA, et al. Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults. Sci Rep 2021;11:5.
215. Aljumaah MR, Bhatia U, Roach J, Gunstad J, Azcarate Peril MA. The gut microbiome, mild cognitive impairment, and probiotics: a randomized clinical trial in middle-aged and older adults. Clin Nutr 2022;41:2565-76.
216. Hwang YH, Park S, Paik JW, et al. Efficacy and safety of Lactobacillus plantarum C29-Fermented Soybean (DW2009) in individuals with mild cognitive impairment: a 12-week, multi-center, randomized, double-blind, placebo-controlled clinical trial. Nutrients 2019;11:305.
217. Kim CS, Cha L, Sim M, et al. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: a randomized, double-blind, placebo-controlled, multicenter trial. J Gerontol A Biol Sci Med Sci 2021;76:32-40.
218. Asaoka D, Xiao J, Takeda T, et al. Effect of probiotic bifidobacterium breve in improving cognitive function and preventing brain atrophy in older patients with suspected mild cognitive impairment: results of a 24-week randomized, double-blind, placebo-controlled trial. J Alzheimers Dis 2022;88:75-95.
219. Fei Y, Wang R, Lu J, et al. Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment. Geriatr Nurs 2023;51:167-75.
220. Shi S, Zhang Q, Sang Y, et al. Probiotic Bifidobacterium longum BB68S improves cognitive functions in healthy older adults: a randomized, double-blind, placebo-controlled trial. Nutrients 2022;15:51.
221. Borges MK, de Castro Cezar NO, Santos Siqueira AS, Yassuda M, Cesari M, Aprahamian I. The relationship between physical frailty and mild cognitive impairment in the elderly: a systematic review. J Frailty Aging 2019;8:192-7.
222. Quintero DF, Kok CR, Hutkins R. The future of synbiotics: rational formulation and design. Front Microbiol 2022;13:919725.
223. Westfall S, Lomis N, Prakash S. Longevity extension in Drosophila through gut-brain communication. Sci Rep 2018;8:8362.
224. Sergeev IN, Aljutaily T, Walton G, Huarte E. Effects of synbiotic supplement on human gut microbiota, body composition and weight loss in obesity. Nutrients 2020;12:222.
225. Tripp ML, Dahlberg CJ, Eliason S, et al. A low-glycemic, mediterranean diet and lifestyle modification program with targeted nutraceuticals reduces body weight, improves cardiometabolic variables and longevity biomarkers in overweight subjects: a 13-week observational trial. J Med Food 2019;22:479-89.
226. Kopp L, Schweinlin A, Tingö L, et al. Potential modulation of inflammation and physical function by combined probiotics, omega-3 supplementation and vitamin d supplementation in overweight/obese patients with chronic low-grade inflammation: a randomized, placebo-controlled trial. Int J Mol Sci 2023;24:8567.
227. Saros L, Vahlberg T, Koivuniemi E, et al. Fish oil and/or probiotics intervention in overweight/obese pregnant women and overweight risk in 24-month-old children. J Pediatr Gastroenterol Nutr 2023;76:218-26.
228. Ford AL, Nagulesapillai V, Piano A, et al. Microbiota stability and gastrointestinal tolerance in response to a high-protein diet with and without a prebiotic, probiotic, and synbiotic: a randomized, double-blind, placebo-controlled trial in older women. J Acad Nutr Diet 2020;120:500-16.e10.
229. Crovesy L, El-Bacha T, Rosado EL. Modulation of the gut microbiota by probiotics and symbiotics is associated with changes in serum metabolite profile related to a decrease in inflammation and overall benefits to metabolic health: a double-blind randomized controlled clinical trial in women with obesity. Food Funct 2021;12:2161-70.
230. Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol 2016;27:439-43.
231. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol 2021;18:649-67.
232. Lu Y, Fan C, Li P, Lu Y, Chang X, Qi K. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci Rep 2016;6:37589.
233. Hildebrand CB, Lichatz R, Pich A, et al. Short-chain fatty acids improve inflamm-aging and acute lung injury in old mice. Am J Physiol Lung Cell Mol Physiol 2023;324:L480-92.
234. Arora K, Green M, Prakash S. The microbiome and Alzheimer’s disease: potential and limitations of prebiotic, synbiotic, and probiotic formulations. Front Bioeng Biotechnol 2020;8:537847.
235. Kahouli I, Malhotra M, Tomaro-Duchesneau C, Rodes LS, Alaoui-Jamali MA, Prakash S. Identification of Lactobacillus Fermentum strains with potential against colorectal cancer by characterizing short chain fatty acids production, anti-proliferative activity and survival in an intestinal fluid: in vitro analysis. J Bioanal Biomed 2015;7:4. Available from: https://hal.science/hal-04021382v1/file/identification-of-lactobacillus-fermentum-strains-with-potential-against-colorectal-cancer-by-characterizing-1948-593X-1000132.pdf. [Last accessed on 15 May 2024]
236. Westfall S, Lomis N, Singh SP, Prakash S. Ferulic acid produced by Lactobacillus fermentum NCIMB 5221 reduces symptoms of metabolic syndrome in Drosophila melanogaster. J Microb Biochem Technol 2016;8:4.
237. de Melo TS, Lima PR, Carvalho KM, et al. Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesity. Braz J Med Biol Res 2017;50:e5630.
238. DiNicolantonio JJ, McCarty MF, Assanga SI, Lujan LL, O’Keefe JH. Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity. Open Heart 2022;9:e001801.
239. Fogelson KA, Dorrestein PC, Zarrinpar A, Knight R. The gut microbial bile acid modulation and its relevance to digestive health and diseases. Gastroenterology 2023;164:1069-85.
240. Prete R, Long SL, Gallardo AL, Gahan CG, Corsetti A, Joyce SA. Beneficial bile acid metabolism from Lactobacillus plantarum of food origin. Sci Rep 2020;10:1165.
241. Mazloom K, Siddiqi I, Covasa M. Probiotics: how effective are they in the fight against obesity? Nutrients 2019;11:258.
242. Pérez-Ramos A, Madi-Moussa D, Coucheney F, Drider D. Current knowledge of the mode of action and immunity mechanisms of LAB-bacteriocins. Microorganisms 2021;9:2107.
243. Ahmad W, Boyajian JL, Abosalha A, et al. High-molecular-weight dextran-type exopolysaccharide produced by the novel Apilactobacillus waqarii improves metabolic syndrome: in vitro and in vivo analyses. Int J Mol Sci 2022;23:12692.
244. Lim J, Kale M, Kim DH, et al. Antiobesity effect of exopolysaccharides isolated from kefir grains. J Agric Food Chem 2017;65:10011-9.
